ID   DHI2_HUMAN              Reviewed;         405 AA.
AC   P80365; A7LB28; C5HTY7; Q13194; Q6P2G9; Q8N439; Q96QN8; Q9UC50;
AC   Q9UC51; Q9UCW5; Q9UCW6; Q9UCW7; Q9UCW8;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   30-APR-2003, sequence version 2.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Corticosteroid 11-beta-dehydrogenase isozyme 2;
DE            EC=1.1.1.-;
DE   AltName: Full=11-beta-hydroxysteroid dehydrogenase type 2;
DE            Short=11-DH2;
DE            Short=11-beta-HSD2;
DE   AltName: Full=11-beta-hydroxysteroid dehydrogenase type II;
DE            Short=11-HSD type II;
DE            Short=11-beta-HSD type II;
DE   AltName: Full=NAD-dependent 11-beta-hydroxysteroid dehydrogenase;
DE            Short=11-beta-HSD;
DE   AltName: Full=Short chain dehydrogenase/reductase family 9C member 3;
GN   Name=HSD11B2; Synonyms=HSD11K {ECO:0000303|PubMed:8530071}, SDR9C3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=7859916; DOI=10.1016/0303-7207(94)90176-7;
RA   Albiston A.L., Obeyesekere V.R., Smith R.E., Krozowski Z.S.;
RT   "Cloning and tissue distribution of the human 11 beta-hydroxysteroid
RT   dehydrogenase type 2 enzyme.";
RL   Mol. Cell. Endocrinol. 105:R11-R17(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8530071; DOI=10.1006/geno.1995.1231;
RA   Agarwal A.K., Rogerson F.M., Mune T., White P.C.;
RT   "Gene structure and chromosomal localization of the human HSD11K gene
RT   encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid
RT   dehydrogenase.";
RL   Genomics 29:195-199(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8611140; DOI=10.1042/bj3131007;
RA   Brown R.W., Chapman K.E., Kotelevtsev Y., Yau J.L., Lindsay R.S.,
RA   Brett L., Leckie C., Murad P., Lyons V., Mullins J.J., Edwards C.R.W.,
RA   Seckl J.R.;
RT   "Cloning and production of antisera to human placental 11 beta-
RT   hydroxysteroid dehydrogenase type 2.";
RL   Biochem. J. 313:1007-1017(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 19-24; 77-84; 102-112; 134-154; 191-198; 214-227;
RP   229-235; 256-266; 272-278 AND 375-401.
RC   TISSUE=Placenta;
RX   PubMed=8611186; DOI=10.1042/bj3130997;
RA   Brown R.W., Chapman K.E., Murad P., Edwards C.R., Seckl J.R.;
RT   "Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from
RT   human placenta utilizing a novel affinity labelling technique.";
RL   Biochem. J. 313:997-1005(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 90-221.
RA   Amin H.K., Hoeppner W.;
RT   "Human hydroxysteroid dehydrogenase type 2 HSD11B2.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 182-211; 235-264 AND 325-354, AND
RP   VARIANTS AME CYS-186; CYS-208; 250-PRO-SER-251 AND 337-ARG-TYR-338
RP   DELINS HIS.
RX   PubMed=7593417; DOI=10.1210/jcem.80.11.7593417;
RA   Wilson R.C., Harbison M.D., Krozowski Z.S., Funder J.W.,
RA   Shackleton C.H.L., Hanauske-Abel H.M., Wei J.-Q., Hertecant J.,
RA   Moran A., Neiberger R.E., Balfe J.W., Fattah A., Daneman D.,
RA   Licholai T., New M.I.;
RT   "Several homozygous mutations in the gene for 11 beta-hydroxysteroid
RT   dehydrogenase type 2 in patients with apparent mineralocorticoid
RT   excess.";
RL   J. Clin. Endocrinol. Metab. 80:3145-3150(1995).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=2889032; DOI=10.1016/S0140-6736(87)91014-2;
RA   Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H.L.,
RA   Edwards C.R.W.;
RT   "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid
RT   dehydrogenase deficiency comes of age.";
RL   Lancet 2:821-824(1987).
RN   [12]
RP   INTERACTION WITH NR3C2.
RX   PubMed=11350956; DOI=10.1074/jbc.M100374200;
RA   Odermatt A., Arnold P., Frey F.J.;
RT   "The intracellular localization of the mineralocorticoid receptor is
RT   regulated by 11beta-hydroxysteroid dehydrogenase type 2.";
RL   J. Biol. Chem. 276:28484-28492(2001).
RN   [13]
RP   VARIANT AME CYS-337.
RX   PubMed=7608290; DOI=10.1210/jcem.80.7.7608290;
RA   Wilson R.C., Krozowski Z.S., Li K., Obeyesekere V.R.,
RA   Razzaghy-Azar M., Harbison M.D., Wei J.-Q., Shackleton C.H.L.,
RA   Funder J.W., New M.I.;
RT   "A mutation in the HSD11B2 gene in a family with apparent
RT   mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 80:2263-2266(1995).
RN   [14]
RP   CHARACTERIZATION OF VARIANTS AME CYS-208; CYS-213; 250-PRO-SER-251 AND
RP   337-ARG-TYR-338 DELINS HIS.
RX   PubMed=7670488; DOI=10.1038/ng0895-394;
RA   Mune T., Rogerson F.M., Nikkilae H., Agarwal A.K., White P.C.;
RT   "Human hypertension caused by mutations in the kidney isozyme of 11
RT   beta-hydroxysteroid dehydrogenase.";
RL   Nat. Genet. 10:394-399(1995).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS AME HIS-208 AND 337-ARG-TYR-338 DELINS
RP   HIS.
RX   PubMed=9398712; DOI=10.1210/jcem.82.12.4455;
RA   Kitanaka S., Katsumata N., Tanae A., Hibi I., Takeyama K., Fuse H.,
RA   Kato S., Tanaka T.;
RT   "A new compound heterozygous mutation in the 11 beta-hydroxysteroid
RT   dehydrogenase type 2 gene in a case of apparent mineralocorticoid
RT   excess.";
RL   J. Clin. Endocrinol. Metab. 82:4054-4058(1997).
RN   [16]
RP   CHARACTERIZATION OF VARIANT AME CYS-279.
RX   PubMed=9683587; DOI=10.1086/301955;
RA   Li A., Tedde R., Krozowski Z.S., Pala A., Li K.X.Z.,
RA   Shackleton C.H.L., Mantero F., Palermo M., Stewart P.M.;
RT   "Molecular basis for hypertension in the 'type II variant' of apparent
RT   mineralocorticoid excess.";
RL   Am. J. Hum. Genet. 63:370-379(1998).
RN   [17]
RP   VARIANTS AME CYS-186; CYS-208; ASN-244; ARG-250; 250-PRO-SER-251;
RP   CYS-337 AND 337-ARG-TYR-338 DELINS HIS.
RX   PubMed=9661590; DOI=10.1210/jcem.83.7.4986;
RA   Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R.,
RA   Krozowski Z.S., Funder J.W., Shackleton C.H.L., Bradlow H.L.,
RA   Wei J.-Q., Hertecant J., Moran A., Neiberger R.E., Balfe J.W.,
RA   Fattah A., Daneman D., Akkurt H.I., De Santis C., New M.I.;
RT   "Examination of genotype and phenotype relationships in 14 patients
RT   with apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 83:2244-2254(1998).
RN   [18]
RP   CHARACTERIZATION OF VARIANT AME CYS-213.
RX   PubMed=9851783; DOI=10.1210/jcem.83.12.5329;
RA   Rogoff D., Smolenicka Z., Bergada I., Vallejo G., Barontini M.,
RA   Heinrich J.J., Ferrari P.;
RT   "The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene
RT   is a hot spot for mutations in apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 83:4391-4393(1998).
RN   [19]
RP   CHARACTERIZATION OF VARIANT HYPERTENSION LEU-227.
RX   PubMed=9707624; DOI=10.1073/pnas.95.17.10200;
RA   Wilson R.C., Dave-Sharma S., Wei J.-Q., Obeyesekere V.R., Li K.,
RA   Ferrari P., Krozowski Z.S., Shackleton C.H.L., Bradlow L., Wiens T.,
RA   New M.I.;
RT   "A genetic defect resulting in mild low-renin hypertension.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10200-10205(1998).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS AME CYS-213 AND VAL-328.
RX   PubMed=10489390; DOI=10.1161/01.HYP.34.3.435;
RA   Morineau G., Marc J.-M., Boudi A., Galons H., Gourmelen M., Corvol P.,
RA   Pascoe L., Fiet J.;
RT   "Genetic, biochemical, and clinical studies of patients with A328V or
RT   R213C mutations in 11betaHSD2 causing apparent mineralocorticoid
RT   excess.";
RL   Hypertension 34:435-441(1999).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS AME ARG-179; PHE-180; HIS-208; VAL-237
RP   AND VAL-328.
RX   PubMed=10523339; DOI=10.1161/01.HYP.34.4.638;
RA   Nunez B.S., Rogerson F.M., Mune T., Igarashi Y., Nakagawa Y.,
RA   Phillipov G., Moudgil A., Travis L.B., Palermo M., Shackleton C.H.L.,
RA   White P.C.;
RT   "Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial
RT   activity: improved correlations between genotype and biochemical
RT   phenotype in apparent mineralocorticoid excess.";
RL   Hypertension 34:638-642(1999).
RN   [22]
RP   CHARACTERIZATION OF VARIANT AME 114-LEU-GLU-115 DEL, AND MUTAGENESIS
RP   OF GLU-115.
RX   PubMed=11238516; DOI=10.1210/jcem.86.3.7334;
RA   Odermatt A., Dick B., Arnold P., Zaehner T., Plueschke V.,
RA   Deregibus M.N., Repetto H., Frey B.M., Frey F.J., Ferrari P.;
RT   "A mutation in the cofactor-binding domain of 11beta-hydroxysteroid
RT   dehydrogenase type 2 associated with mineralocorticoid hypertension.";
RL   J. Clin. Endocrinol. Metab. 86:1247-1252(2001).
RN   [23]
RP   VARIANT AME ASN-223, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12788846; DOI=10.1210/jc.2002-021909;
RA   Carvajal C.A., Gonzalez A.A., Romero D.G., Gonzalez A., Mosso L.M.,
RA   Lagos E.T., Hevia Mdel P., Rosati M.P., Perez-Acle T.O.,
RA   Gomez-Sanchez C.E., Montero J.A., Fardella C.E.;
RT   "Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase
RT   type 2 gene in a case of apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 88:2501-2507(2003).
RN   [24]
RP   VARIANTS AME CYS-337 AND HIS-338, SUBCELLULAR LOCATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ARG-335; ARG-336;
RP   ARG-337; TYR-338 AND TYR-339.
RX   PubMed=17314322; DOI=10.1681/ASN.2006111235;
RA   Atanasov A.G., Ignatova I.D., Nashev L.G., Dick B., Ferrari P.,
RA   Frey F.J., Odermatt A.;
RT   "Impaired protein stability of 11beta-hydroxysteroid dehydrogenase
RT   type 2: a novel mechanism of apparent mineralocorticoid excess.";
RL   J. Am. Soc. Nephrol. 18:1262-1270(2007).
CC   -!- FUNCTION: Catalyzes the conversion of cortisol to the inactive
CC       metabolite cortisone. Modulates intracellular glucocorticoid
CC       levels, thus protecting the nonselective mineralocorticoid
CC       receptor from occupation by glucocorticoids.
CC   -!- CATALYTIC ACTIVITY: An 11-beta-hydroxysteroid + NAD(+) = an 11-
CC       oxosteroid + NADH.
CC   -!- ENZYME REGULATION: Inhibited by glycyrrhetinic acid (derived from
CC       liquorice), carbenoloxone and 11-alpha-OH-progesterone.
CC       {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=26.1 nM for cortisol {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         KM=785 nM for cortisol {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         KM=77 nM for cortisterone {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         Vmax=64.1 nmol/h/mg enzyme toward cortisterone
CC         {ECO:0000269|PubMed:12788846, ECO:0000269|PubMed:17314322};
CC         Vmax=66 nmol/h/mg enzyme toward cortisol
CC         {ECO:0000269|PubMed:12788846, ECO:0000269|PubMed:17314322};
CC   -!- SUBUNIT: Interacts with ligand-free cytoplasmic NR3C2.
CC       {ECO:0000269|PubMed:11350956}.
CC   -!- SUBCELLULAR LOCATION: Microsome {ECO:0000269|PubMed:17314322}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:17314322}.
CC   -!- TISSUE SPECIFICITY: Expressed in kidney, pancreas, prostate,
CC       ovary, small intestine and colon. At midgestation, expressed at
CC       high levels in placenta and in fetal kidney and, at much lower
CC       levels, in fetal lung and testis (PubMed:8530071).
CC       {ECO:0000269|PubMed:8530071}.
CC   -!- DISEASE: Apparent mineralocorticoid excess (AME) [MIM:218030]: An
CC       autosomal recessive form of low-renin hypertension. It is usually
CC       diagnosed within the first years of life and is characterized by
CC       polyuria and polydipsia, failure to thrive, hypernatremia, severe
CC       hypertension with low renin and aldosterone levels, profound
CC       hypokalemia with metabolic alkalosis, and most often
CC       nephrocalcinosis. {ECO:0000269|PubMed:10489390,
CC       ECO:0000269|PubMed:10523339, ECO:0000269|PubMed:11238516,
CC       ECO:0000269|PubMed:12788846, ECO:0000269|PubMed:17314322,
CC       ECO:0000269|PubMed:7593417, ECO:0000269|PubMed:7608290,
CC       ECO:0000269|PubMed:7670488, ECO:0000269|PubMed:9398712,
CC       ECO:0000269|PubMed:9661590, ECO:0000269|PubMed:9683587,
CC       ECO:0000269|PubMed:9851783}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Consumption of large amounts of liquorice can lead
CC       to apparent mineralocorticoid excess and hypertension.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U14631; AAA91969.1; -; mRNA.
DR   EMBL; U27317; AAB48544.1; -; Genomic_DNA.
DR   EMBL; U26726; AAC50356.1; -; mRNA.
DR   EMBL; EF694683; ABS29267.1; -; Genomic_DNA.
DR   EMBL; FJ515828; ACS13714.1; -; Genomic_DNA.
DR   EMBL; CH471092; EAW83134.1; -; Genomic_DNA.
DR   EMBL; BC036780; AAH36780.1; -; mRNA.
DR   EMBL; BC064536; AAH64536.1; -; mRNA.
DR   EMBL; AY046280; AAK91586.1; -; Genomic_DNA.
DR   CCDS; CCDS10837.1; -.
DR   PIR; S62789; S62789.
DR   RefSeq; NP_000187.3; NM_000196.3.
DR   UniGene; Hs.1376; -.
DR   ProteinModelPortal; P80365; -.
DR   SMR; P80365; -.
DR   BioGrid; 109524; 4.
DR   STRING; 9606.ENSP00000316786; -.
DR   BindingDB; P80365; -.
DR   ChEMBL; CHEMBL3746; -.
DR   DrugBank; DB00157; NADH.
DR   SwissLipids; SLP:000000810; -.
DR   iPTMnet; P80365; -.
DR   PhosphoSitePlus; P80365; -.
DR   BioMuta; HSD11B2; -.
DR   DMDM; 30316367; -.
DR   EPD; P80365; -.
DR   MaxQB; P80365; -.
DR   PaxDb; P80365; -.
DR   PeptideAtlas; P80365; -.
DR   PRIDE; P80365; -.
DR   Ensembl; ENST00000326152; ENSP00000316786; ENSG00000176387.
DR   GeneID; 3291; -.
DR   KEGG; hsa:3291; -.
DR   UCSC; uc002etd.4; human.
DR   CTD; 3291; -.
DR   DisGeNET; 3291; -.
DR   GeneCards; HSD11B2; -.
DR   HGNC; HGNC:5209; HSD11B2.
DR   HPA; CAB032443; -.
DR   HPA; HPA042186; -.
DR   HPA; HPA056385; -.
DR   MalaCards; HSD11B2; -.
DR   MIM; 218030; phenotype.
DR   MIM; 614232; gene.
DR   neXtProt; NX_P80365; -.
DR   OpenTargets; ENSG00000176387; -.
DR   Orphanet; 320; Apparent mineralocorticoid excess.
DR   PharmGKB; PA29477; -.
DR   eggNOG; KOG1610; Eukaryota.
DR   eggNOG; ENOG410Y7FK; LUCA.
DR   GeneTree; ENSGT00870000136397; -.
DR   HOVERGEN; HBG005482; -.
DR   InParanoid; P80365; -.
DR   KO; K00071; -.
DR   OMA; NAGHNEV; -.
DR   OrthoDB; EOG091G0LMI; -.
DR   PhylomeDB; P80365; -.
DR   TreeFam; TF325617; -.
DR   BRENDA; 1.1.1.B40; 2681.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   SABIO-RK; P80365; -.
DR   ChiTaRS; HSD11B2; human.
DR   GeneWiki; Corticosteroid_11-beta-dehydrogenase_isozyme_2; -.
DR   GenomeRNAi; 3291; -.
DR   PRO; PR:P80365; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000176387; -.
DR   CleanEx; HS_HSD11B2; -.
DR   ExpressionAtlas; P80365; baseline and differential.
DR   Genevisible; P80365; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0003845; F:11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity; TAS:Reactome.
DR   GO; GO:0051287; F:NAD binding; IEA:Ensembl.
DR   GO; GO:0005496; F:steroid binding; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0002017; P:regulation of blood volume by renal aldosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Endoplasmic reticulum; Microsome; NAD; Oxidoreductase; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    405       Corticosteroid 11-beta-dehydrogenase
FT                                isozyme 2.
FT                                /FTId=PRO_0000054627.
FT   NP_BIND      82    111       NAD. {ECO:0000250}.
FT   REGION      335    339       Essential for protein stability.
FT   ACT_SITE    232    232       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10001}.
FT   BINDING     219    219       Substrate. {ECO:0000250}.
FT   VARIANT     114    115       Missing (in AME; reduces enzyme activity
FT                                by at least 95%).
FT                                {ECO:0000269|PubMed:11238516}.
FT                                /FTId=VAR_015634.
FT   VARIANT     147    147       R -> H (in dbSNP:rs13306425).
FT                                /FTId=VAR_052317.
FT   VARIANT     179    179       L -> R (in AME; abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:10523339}.
FT                                /FTId=VAR_015635.
FT   VARIANT     180    180       S -> F (in AME; reduces enzyme activity).
FT                                {ECO:0000269|PubMed:10523339}.
FT                                /FTId=VAR_015636.
FT   VARIANT     186    186       R -> C (in AME; dbSNP:rs768507002).
FT                                {ECO:0000269|PubMed:7593417,
FT                                ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_015637.
FT   VARIANT     208    208       R -> C (in AME; reduces enzyme activity
FT                                by at least 95%; dbSNP:rs121917780).
FT                                {ECO:0000269|PubMed:7593417,
FT                                ECO:0000269|PubMed:7670488,
FT                                ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_006958.
FT   VARIANT     208    208       R -> H (in AME; abolishes enzyme
FT                                activity; dbSNP:rs28934592).
FT                                {ECO:0000269|PubMed:10523339,
FT                                ECO:0000269|PubMed:9398712}.
FT                                /FTId=VAR_015638.
FT   VARIANT     213    213       R -> C (in AME; reduces enzyme activity
FT                                by 90%; dbSNP:rs28934591).
FT                                {ECO:0000269|PubMed:10489390,
FT                                ECO:0000269|PubMed:7670488,
FT                                ECO:0000269|PubMed:9851783}.
FT                                /FTId=VAR_006959.
FT   VARIANT     223    223       D -> N (in AME; reduces enzyme activity
FT                                to about 6% of wild type;
FT                                dbSNP:rs121917833).
FT                                {ECO:0000269|PubMed:12788846}.
FT                                /FTId=VAR_066514.
FT   VARIANT     227    227       P -> L (in hypertension; decreases
FT                                affinity for cortisol;
FT                                dbSNP:rs121917782).
FT                                {ECO:0000269|PubMed:9707624}.
FT                                /FTId=VAR_015639.
FT   VARIANT     237    237       A -> V (in AME; reduces enzyme activity).
FT                                {ECO:0000269|PubMed:10523339}.
FT                                /FTId=VAR_015640.
FT   VARIANT     244    244       D -> N (in AME; associated with R-250).
FT                                {ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_015641.
FT   VARIANT     250    251       LL -> PS (in AME; abolishes enzyme
FT                                activity).
FT                                /FTId=VAR_015643.
FT   VARIANT     250    250       L -> R (in AME; associated with N-244).
FT                                {ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_015642.
FT   VARIANT     279    279       R -> C (in AME; decreases enzyme activity
FT                                by 33%; dbSNP:rs28934594).
FT                                {ECO:0000269|PubMed:9683587}.
FT                                /FTId=VAR_015644.
FT   VARIANT     328    328       A -> V (in AME; abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:10489390,
FT                                ECO:0000269|PubMed:10523339}.
FT                                /FTId=VAR_015645.
FT   VARIANT     337    338       RY -> H (in AME; abolishes enzyme
FT                                activity). {ECO:0000269|PubMed:7593417,
FT                                ECO:0000269|PubMed:7670488,
FT                                ECO:0000269|PubMed:9398712,
FT                                ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_015647.
FT   VARIANT     337    337       R -> C (in AME; decreased half-life from
FT                                21 to 4 hours compared to wild-type,
FT                                probably due to degradation via the
FT                                proteasomal pathway; dbSNP:rs121917781).
FT                                {ECO:0000269|PubMed:17314322,
FT                                ECO:0000269|PubMed:7608290,
FT                                ECO:0000269|PubMed:9661590}.
FT                                /FTId=VAR_066515.
FT   VARIANT     338    338       Y -> H (in AME; abolishes enzyme
FT                                activity; decreased half-life from 21 to
FT                                3 hours compared to wild-type, probably
FT                                due to degradation via the proteasomal
FT                                pathway; dbSNP:rs387907117).
FT                                {ECO:0000269|PubMed:17314322}.
FT                                /FTId=VAR_015646.
FT   MUTAGEN     115    115       E->K,Q: Abolishes cofactor specificity.
FT                                {ECO:0000269|PubMed:11238516}.
FT   MUTAGEN     335    335       R->A,Q: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     335    335       R->K: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     336    336       R->A,Q: Almost complete loss of enzyme
FT                                activity. {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     336    336       R->K: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     337    337       R->A,Q: Almost complete loss of enzyme
FT                                activity. {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     337    337       R->K: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     338    338       Y->F,A: Complete loss of enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   MUTAGEN     339    339       Y->A,F,H: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:17314322}.
FT   CONFLICT    148    148       V -> F (in Ref. 2; AAB48544).
FT                                {ECO:0000305}.
FT   CONFLICT    148    148       V -> L (in Ref. 1; AAA91969).
FT                                {ECO:0000305}.
FT   CONFLICT    350    350       I -> T (in Ref. 7; AAH64536).
FT                                {ECO:0000305}.
FT   CONFLICT    392    392       D -> G (in Ref. 7; AAH36780).
FT                                {ECO:0000305}.
SQ   SEQUENCE   405 AA;  44127 MW;  4AB269E269982D24 CRC64;
     MERWPWPSGG AWLLVAARAL LQLLRSDLRL GRPLLAALAL LAALDWLCQR LLPPPAALAV
     LAAAGWIALS RLARPQRLPV ATRAVLITGC DSGFGKETAK KLDSMGFTVL ATVLELNSPG
     AIELRTCCSP RLRLLQMDLT KPGDISRVLE FTKAHTTSTG LWGLVNNAGH NEVVADAELS
     PVATFRSCME VNFFGALELT KGLLPLLRSS RGRIVTVGSP AGDMPYPCLG AYGTSKAAVA
     LLMDTFSCEL LPWGVKVSII QPGCFKTESV RNVGQWEKRK QLLLANLPQE LLQAYGKDYI
     EHLHGQFLHS LRLAMSDLTP VVDAITDALL AARPRRRYYP GQGLGLMYFI HYYLPEGLRR
     RFLQAFFISH CLPRALQPGQ PGTTPPQDAA QDPNLSPGPS PAVAR
//
